XTX Topco’s Cartesian Therapeutics RNAC Stock Holding History

XTX Topco’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$185K	Buy	30,055 +19,817	+194%	+$141K	﹤0.01%	2872
2025 Q4	$73.8K	Sell	10,238 -16,021	-61%	-$130K	﹤0.01%	2728
2025 Q3	$0	Buy	+26,259	New	+$295K	﹤0.01%	3160
2024 Q1	–	Sell	-1,195	Closed	-$24.7K	–	2244
2023 Q4	$24.7K	Sell	1,195 -1,638	-58%	-$48.9K	0.01%	1339
2023 Q3	$90.1K	Sell	2,833 -2,108	-43%	-$70.4K	0.02%	1197
2023 Q2	$166K	Buy	+4,941	New	+$177K	0.03%	1073
2023 Q1	–	Sell	-6,226	Closed	-$211K	–	1609
2022 Q4	$211K	Sell	6,226 -165	-3%	-$7.02K	0.04%	808
2022 Q3	$314K	Buy	6,391 +3,910	+158%	+$215K	0.08%	471
2022 Q2	$97K	Sell	2,481 -1,573	-39%	-$46.6K	0.04%	655
2022 Q1	$150K	Buy	4,054 +2,934	+262%	+$184K	0.07%	459
2021 Q4	$110K	Buy	+1,120	New	+$120K	0.06%	455
2021 Q3	–	Sell	-1,063	Closed	-$133K	–	1011
2021 Q2	$133K	Buy	+1,063	New	+$127K	0.04%	626

Other funds holding RNAC

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

XTX Topco's RNAC Position: Q1 2026 in Review

XTX Topco increased its Cartesian Therapeutics (RNAC) stake by 194% in Q1 2026, buying an estimated $141K and bringing the position to 30,055 shares worth $185K. The position accounts for ﹤0.01% of the portfolio, ranked #2872.

XTX Topco first reported a position in RNAC in Q2 2021 and has held it in 12 quarters since. The position peaked at $314K in Q3 2022. 83 funds tracked by Wall St. Rank hold RNAC as of Q1 2026.

XTX Topco held 30,055 shares of Cartesian Therapeutics worth $185K as of Q1 2026.
XTX Topco bought 19,817 Cartesian Therapeutics shares in Q1 2026, an estimated $141K.
Cartesian Therapeutics made up ﹤0.01% of XTX Topco's portfolio in Q1 2026, its #2872 holding.
XTX Topco first reported a position in Cartesian Therapeutics in Q2 2021 and has held it in 12 quarters since.
XTX Topco's Cartesian Therapeutics position peaked at $314K in Q3 2022.
83 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.